BioMarin investing $43M in fill-finish line at plant in Ireland

BioMarin's plant in Ireland is the first outside the U.S. for the genetic disease specialist. (BioMarin)

BioMarin had its first manufacturing site outside of the U.S. approved just last year. But the genetic disease specialist is already expanding the site in Ireland and adding dozens of new jobs.

The drugmaker will invest about $43 million in a filling line at the bulk biologics plant in Shanbally, County Cork, and is expected to bring on 51 employees as a result, according to an announcement from the Ireland Development Agency.

The new filling line will supplement its drug substance manufacturing and secondary packaging and labeling capabilities. It already has about 350 workers at the facility.


Simplify and Accelerate Drug R&D With the MarkLogic Data Hub Service for Pharma R&D

Researchers are often unable to access the information they need. And, even when data does get consolidated, researchers find it difficult to sift through it all and make sense of it in order to confidently draw the right conclusions and share the right results. Discover how to quickly and easily find, synthesize, and share information—accelerating and improving R&D.

“The introduction of fill finish capacity at Shanbally provides for fully integrated manufacturing from bulk to drug product onsite,” BioMarin Executive VP Robert Baffi, Ph.D., said in a statement. “This expansion assures that an increasing amount of our commercial products will be manufactured at the site.”

RELATED: FDA gives nod to BioMarin’s Ireland bulk biologic manufacturing facility 

BioMarin bought the operation from Pfizer in 2011 to diversify its manufacturing risk. The site has already been expanded to include an expanded warehouse, utilities and new office space. Last year, it moved manufacturing of Vimizim, its drug for Morquio A syndrome, an enzyme deficiency that interferes with skeletal development and can trigger a host of other health problems.

Suggested Articles

The efficacy between Keytruda and FerGene's nadofaragene firadenovec look comparable in their studies, though Merck has at least one upper hand.

Thursday, the FDA approved the first three generic versions of Gilenya, but they may not hit the market anytime soon due to ongoing litigation.

Gilead is hoping to score a patent extension on TAF meds, but patient advocates say that would reward conduct that harmed patients.